A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Study to Explore the Safety and Efficacy of ALS-L1023 in Patients With Non-alcoholic Steatohepatitis (NASH)
Latest Information Update: 28 Dec 2023
At a glance
- Drugs ALS L1023 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors AngioLab Inc
Most Recent Events
- 14 Nov 2023 Results assessing efficacy and safety of ALS-L1023 for the treatment of non-alcoholic fatty liver disease, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 09 Aug 2022 Status changed from recruiting to completed.
- 11 Jan 2021 Planned End Date changed from 4 Dec 2020 to 30 Sep 2021.